Avenue Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

		*For the years ended December 31,*
		*2024*				*2023*
Statutory federal income tax rate			21	%			21	%
State taxes, net of federal tax benefit			0	%			11	%
State rate change			(14	)%			1	%
Stock-based compensation			0	%			0	%
Other			0	%			0	%
Credits			1	%			1	%
None-deductible items			1	%			(1	)%
Return to provision			(12	)%			0	%
Section 162(m) disallowance			0	%			0	%
Change in fair value of warrant liability			(2	)%			12	%
Change in valuation allowance			6	%			(45	)%
Income taxes provision (benefit)			0	%			0	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

		*As of December 31,*
		*2024*				*2023*
Deferred tax assets:
Net operating loss carryforwards		$	27,114			$	27,318
Stock compensation and other			404				287
In process research and development			1,929				2,884
Accruals and reserves			3				4
Business interest expense disallowance			—				—
Section 174 capitalization			2,536				2,253
Tax credits			2,995				2,926
Total deferred tax assets			34,981				35,672
Less valuation allowance			(34,981	)			(35,672	)
Deferred tax assets, net of valuation allowance		$	—			$	—